While they produce modest LDL cholesterol reductions of 2-10%, statins remain first-line therapy for patients requiring significant lipid lowering, and GLP-1 agents work best as complementary therapy alongside statins
While head-to-head comparison is lacking, CagriSema seems more effective in promoting weight reduction than the dual agonist of GLP-1R and gastric inhibitory polypeptide (GIP) receptor, tirzepatide (table 2)
The Muscle, Performance & Body Composition Blueprint explains how combination strategies fit different goals, and why stacking without a framework often backfires
The universally accepted standard, supported by USP (United States Pharmacopeia) guidelines and manufacturers, is 28 days
doi: 10.1002/aur.201 170 WalshPElsabbaghMBoltonPSinghI
Trends in weight regain following Roux-en-Y gastric bypass (RYGB) bariatric surgery